INVO Fertility Inc. has released its unaudited pro forma financial statements reflecting the divestiture of its majority holdings in NAYA Therapeutics Inc. $(NTI.AU)$. The NTI Divestiture, consummated on June 2, 2025, involved the redemption of Series C-1 Non-Voting Convertible Preferred Stock in exchange for shares of Class A Common Stock of NTI. The pro forma financials, which include a consolidated balance sheet as of March 31, 2025, and statements of operations for the three months ended March 31, 2025, and the year ended December 31, 2024, provide insights into INVO's financial condition post-divestiture. The statements are intended for informational purposes and should be read alongside INVO's historical financial reports.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.